Tusamitamab Biosimilar - Research Grade

Human

CEACAM5

>1mg/ml

Human IgG1 (E356D/M358L)-Kappa

Labetuzumab Biosimilar - Research Grade (ICH5120), Altumomab Biosimilar - Research Grade (ICH5340), Arcitumomab Biosimilar - Research Grade (ICH5354), Labetuzumab Govitecan Biosimilar - Research Grade (ICH5617G), Precemtabart Biosimilar - Research Grade (ICH5787)

https://www.imgt.org/mAb-DB/

ICH3002

P06731

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of tusamitamab, supplied for research use only. It is a full-length human IgG1-kappa antibody engineered to recognise human CEACAM5 (carcinoembryonic antigen, UniProt P06731), the same target as the originator ADC tusamitamab ravtansine. Because it is delivered as the naked antibody without the maytansinoid DM4 payload or SPDB linker, it functions purely as a research reagent for interrogating CEACAM5 biology and is not intended for human or veterinary use. It is manufactured at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support reproducible, large-scale experiments. Typical uses include serving as a defined binding reagent, a positive control or isotype-matched benchmark, a capture/detection tool for CEACAM5-expressing lines, and a starting scaffold for ADC and conjugation development. Its consistent, low-endotoxin format makes it well suited to in-vitro assays and preclinical model characterisation where lot-to-lot reproducibility matters. CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, classically CEA; UniProt P06731) is a GPI-anchored cell-surface glycoprotein of the immunoglobulin superfamily and the CEACAM family. It comprises an N-terminal IgV-like domain plus multiple IgC2-like domains and is heavily glycosylated. Functionally it mediates homotypic and heterotypic cell-cell adhesion and modulates cell differentiation, proliferation, polarity and anoikis resistance. Expression is normally restricted to the apical surface of epithelia, particularly in the gastrointestinal tract, but it is strongly and aberrantly overexpressed across many epithelial carcinomas, including colorectal, non-small-cell lung (notably adenocarcinoma), gastric and pancreatic tumours. This tumour-associated overexpression, combined with efficient internalisation upon antibody engagement, makes CEACAM5 an attractive target for antibody-drug conjugates and other targeted modalities.

Carcinoembryonic antigen, CEA, Carcinoembryonic antigen-related cell adhesion molecule 5, CEA cell adhesion molecule 5, Meconium antigen 100, Cell adhesion molecule CEACAM5

Detects human CEACAM5. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tusamitamab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Tusamitamab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Tusamitamab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Tusamitamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Tusamitamab that binds human CEACAM5.